Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Doles Out $339K in Cash Bonuses to Top Brass

NEW YORK, March 24 (GenomeWeb News) - Cepheid's top officals are being offered cash incentives to complete certain company objectives, according to an 8-K filing with the US Securities and Exchange Commission yesterday.

 

According to the filing, Cepheid's CEO John Bishop is eligible to receive a cash incentive payment of $160,000, or 40 percent of his base salary for fiscal year 2006. The incentive is based 50 percent on Cepheid's achievement of a specific revenue and net income and 50 percent on Cepheid's completion of certain corporate objectives related to the company's gross margin metrics. It's also based on the firm's manufacturing expansion plan and its position in the clinical market.

 

Cepheid's chief medical and technology officer, David Persing, is guaranteed an incentive bonus of $122,500, or 35 percent of his base salary for fiscal year 2006, in accordance with his employment letter dated July 21, 2005. The bonus is based on Cepheid's achievement of certain product development and release objectives, its completion of certain research and development tasks, the initiation of certain research programs, and the promotion of technology, Cepheid said.

 

Cepheid's Senior Vice President of sales and marketing, Robert Koska, is eligible to receive a cash incentive bonus of $56,250, or 25 percent of his 2006 base salary. The bonus is based 60 percent on Cepheid's product sales performance, and 40 percent on the attainment of certain departmental marketing, sales, and service objectives, the company said.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.